88. Fostamatinib for the Treatment of Hospitalized Patients With COVID-19 Who Required Oxygen Supplementation: Results of a Phase 3 Trial

BACKGROUND: Severe COVID-19 is linked to hyperactivation of the host immune response involving signaling through multiple spleen tyrosine kinase (SYK) pathways. Fostamatinib is an orally administered potent and selective inhibitor of SYK that has been approved in the US, Canada, Japan, and Europe fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gotur, Deepa B, Malik, Anuj, Markovtsov, Vadim, Yan, Lucy, Dummer, Wolfgang, Mallat, Ziad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677048/
http://dx.doi.org/10.1093/ofid/ofad500.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677048/
http://dx.doi.org/10.1093/ofid/ofad500.004

Ejemplares similares